Folate-Coated Nanoparticles Boost Oral Blood Pressure Peptide Absorption 30-Fold
Folate-decorated lipid nanoparticles increased oral bioavailability of an ACE-inhibiting peptide by 30.7-fold and maintained blood pressure lowering for 6 days in rats.
Quick Facts
What This Study Found
FA-VP5-LNPs achieved 30.71-fold higher oral bioavailability (AUC0-72h) than free VP5 peptide and sustained antihypertensive effects for 6 days.
Key Numbers
30.71x bioavailability improvement; 6-day antihypertensive effect; folate-PLGA-lipid nanoparticles; no toxicity
How They Did This
Nanoparticle formulation (PLGA core + folate-lipid shell), in vitro release studies, Caco-2/HT29 cell uptake, in situ rat intestinal absorption, in vivo pharmacokinetics, and blood pressure monitoring in rat hypertension model.
Why This Research Matters
Oral peptide delivery is a major pharmaceutical challenge. A 30-fold bioavailability improvement with sustained 6-day activity could transform how peptide drugs are administered.
The Bigger Picture
Most peptide drugs require injection because they're destroyed in the gut. Nanoparticle delivery systems like this could enable oral versions of many injectable peptide therapies beyond just blood pressure.
What This Study Doesn't Tell Us
Rat study with unspecified group sizes; folate receptor expression varies between species; long-term safety and manufacturing scalability not assessed; only one peptide tested.
Questions This Raises
- ?Could this nanoparticle platform deliver other therapeutic peptides orally (GLP-1, insulin)?
- ?How does the folate-targeting mechanism work in human intestinal epithelium?
- ?What is the manufacturing cost compared to conventional ACE inhibitor pills?
Trust & Context
- Key Stat:
- 30.7x bioavailability Folate-lipid nanoparticles increased oral peptide absorption 30.71-fold over free peptide in rats
- Evidence Grade:
- Moderate — comprehensive preclinical study with PK, PD, and safety data, but in rats only with unspecified group sizes.
- Study Age:
- Published in 2020; oral peptide delivery technology continues to advance rapidly.
- Original Title:
- An efficient controlled release strategy for hypertension therapy: Folate-mediated lipid nanoparticles for oral peptide delivery.
- Published In:
- Pharmacological research, 157, 104796 (2020)
- Authors:
- Li, Jinhua, Chen, Bin(2), Yu, Ting(3), Guo, Mengran, Zhao, Shengnan, Zhang, Yi, Jin, Chaohui, Peng, Xingchen, Zeng, Jun, Yang, Jian, Song, Xiangrong
- Database ID:
- RPEP-04945
Evidence Hierarchy
Frequently Asked Questions
Why can't you just swallow peptide drugs?
Stomach acid and digestive enzymes destroy peptides before they can be absorbed. Nanoparticle capsules protect peptides through the gut and help them cross the intestinal wall.
How does folate help?
Intestinal cells have folate receptors on their surface. Coating nanoparticles with folate helps them attach to and get absorbed by intestinal cells more efficiently.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04945APA
Li, Jinhua; Chen, Bin; Yu, Ting; Guo, Mengran; Zhao, Shengnan; Zhang, Yi; Jin, Chaohui; Peng, Xingchen; Zeng, Jun; Yang, Jian; Song, Xiangrong. (2020). An efficient controlled release strategy for hypertension therapy: Folate-mediated lipid nanoparticles for oral peptide delivery.. Pharmacological research, 157, 104796. https://doi.org/10.1016/j.phrs.2020.104796
MLA
Li, Jinhua, et al. "An efficient controlled release strategy for hypertension therapy: Folate-mediated lipid nanoparticles for oral peptide delivery.." Pharmacological research, 2020. https://doi.org/10.1016/j.phrs.2020.104796
RethinkPeptides
RethinkPeptides Research Database. "An efficient controlled release strategy for hypertension th..." RPEP-04945. Retrieved from https://rethinkpeptides.com/research/li-2020-an-efficient-controlled-release
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.